Histone deacetylase inhibitor attenuates neurotoxicity of clioquinol in PC12 cells

Toxicology

Volumn 331, Issue , 2015, Pages 112-118

  Fukui, Takao ^a   Asakura, Kunihiko ^a   Hikichi, Chika ^a   Ishikawa, Tomomasa ^a   Murai, Rie ^a   Hirota, Seiko ^a   Murate, Ken ichiro ^a   Kizawa, Madoko ^a   Ueda, Akihiro ^a   Ito, Shinji ^a   Mutoh, Tatsuro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clioquinol; Deacetylation of histones; Histone deacetylase inhibitor; Subacute myeloopticoneuropathy

Indexed keywords

CLIOQUINOL; HISTONE; NERVE GROWTH FACTOR; TRICHOSTATIN A; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; NEUROPROTECTIVE AGENT; PROTEIN TYROSINE KINASE A;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL PROTECTION; CONTROLLED STUDY; DEACETYLATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; NERVE CELL LESION; NERVE FIBER GROWTH; NEUROPROTECTION; NEUROTOXICITY; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; ACETYLATION; ANIMAL; CELL DEATH; CELL SHAPE; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TIME;

ACETYLATION; ANIMALS; CELL DEATH; CELL SHAPE; CLIOQUINOL; CYTOPROTECTION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; NEURONS; NEUROPROTECTIVE AGENTS; PC12 CELLS; PHOSPHORYLATION; RATS; RECEPTOR, TRKA; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84925310885     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2015.01.013     Document Type: Article

References (34)

1. Asakura K., Ueda A., Kawamura N., Ueda M., Mihara T., Mutoh T. Clioquinol inhibits NGF-induced Trk autophosphorylation and neurite outgrowth in PC12 cells. Brain Res. 2009, 1301:110-115.
2. Boyault C., Zhang Y., Fritah S., Caron C., Gilquin B., Kwon S.H., Garrido C., Yao T.P., Vourc'h C., Matthias P., Khochbin S. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 2007, 21:2172-2181.
3. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., Gray S.G., Imitola J., Duran G., Assaf B., Langley B., Khoury S.J., Stephanopoulos G., De Girolami U., Ratan R.R., Ferrante R.J., Dangond F. Transcriptional therapy with the histone deacetylase inhibitor Trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164:10-21.
4. Cao B., Li J., Zhu J., Shen M., Han K., Zhang Z., Yu Y., Wang Y., Wu D., Chen S., Sun A., Tang X., Zhao Y., Qiao C., Hou T., Mao X. The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity. J. Biol. Chem. 2013, 288:34181-34189.
5. Chen D., Cui Q.C., Yang H., Barrea R.A., Sarkar F.H., Sheng S., Yan B., Reddy G.P., Dou Q.P. Clioquinol a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res. 2007, 67:1636-1644.
6. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
7. Dietz K.C., Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol. Res. 2010, 62:11-17.
8. Fischer A., Sananbenesi F., Mungenast A., Tsai L.H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 2010, 31:605-617.
9. Godena V.K., Brookes-Hocking N., Moller A., Shaw G., Oswald M., Sancho R.M., Miller C.C.J., Whitworth A.J., De Vos K.J. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LKK2 Roc-COR domain mutations. Nat. Commun. 2014, 5:5245. 10.1038/ncomms6245.
10. Gräff J., Tsai L.H. Histone acetylation: molecular mnemonics on the chromatin. Nat. Rev. Neurosci. 2013, 14:97-111.
11. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10:32-42.
12. Katsuyama M., Iwata K., Ibi M., Matsuno K., Matsumoto M., Yabe-Nishimura C. Clioquinol induces DNA double-strand breaks, activation of ATM, and subsequent activation of p53 signaling. Toxicology 2012, 299:55-59.
13. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
14. Kawamura K., Kuroda Y., Sogo M., Fujimoto M., Inui T., Mitsui T. Superoxide dismutase as a target of clioquinol-induced neurotoxicity. Biochem. Biophys. Res. Commun. 2014, 452:181-185.
15. Konagaya M., Matsumoto A., Takase S., Mizutani T., Sobue G., Konishi T., Hayabara T., Iwashita H., Ujihira T., Miyata K., Matsuoka Y. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban. J. Neurol. Sci. 2004, 218:85-90.
16. Lahm A., Paolini C., Pallaoro M., Nardi M.C., Jones P., Neddermann P., Sambucini S., Bottomley M.J., Lo Surdo P., Carfí A., Koch U., De Francesco R., Steinkühler C., Gallinari P. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. 2007, 104:17335-17340.
17. Lu J., Yang C., Chen M., Ye D.Y., Lonser R.R., Brady R.O., Zhuang Z. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:21200-21205.
18. Lu J., Frerich J.M., Turtzo L.C., et al. Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury. Proc. Nat. Acad. Sci. U. S. A. 2013, 110:10747-10752.
19. Matsuki Y., Yoshimura S., Abe M. SMON and pharmacokinetics of chinoform with special reference to animal species difference. Yakugaku Zasshi 1997, 7:936-956. [in Japanese with English abstract].
20. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
21. Mutoh T., Hamano T., Tokuda A., Kuriyama M. Unglycosylated Trk protein does not co-localize nor associate with ganglioside GM1 in stable clone of PC12 cells overexpressing Trk (PCtrk cells). Glycoconj. J. 2000, 17:233-237.
22. Mutoh T., Tokuda A., Miyadai T., Hamaguchi M., Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Nat. Acad. Sci. U. S. A. 1995, 92:5087-5091.
23. Nakae K., Yamamoto S., Shigematsu I., Kono R. Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey. Lancet 1973, 1:171-173.
24. Nguyen T., Hamby A., Massa S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11840-11856.
25. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003, 60:1685-1691.
26. Shiraki H., et al. Neuropathological aspects of the etiopathogenesis of subacute myelo-optico-neuropathy (SMON). Intoxications of the Nervous System: Part 2. Handbook of Clinical Neurology 1979, vol. 37:141-198. North-Holland, Amsterdam.
27. Sobue I., et al. Clinical aspects of subacute myelo-optico-neuropathy (SMON). Intoxications of the Nervous System: Part 2. Handbook of Clinical Neurology 1979, vol. 37:115-139. North-Holland, Amsterdam.
28. Sung Y.M., Lee T., Yoon H., et al. Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp. Neurol. 2013, 239:192-201.
29. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 2000, (Suppl. 20):S20-S24.
30. Tsubaki T., Honma Y., Hoshi M. Neurological syndrome associated with clioquinol. Lancet 1971, 1:696-697.
31. Vashishta A., Hetman M. Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage. Neuromol. Med. 2014, 16:727-741.
32. Ververis K., Karagiannis T.C. Potential non-oncological applications of histone deacetylase inhibitors. Am. J. Transl. Res. 2011, 3:454-467.
33. Walkinshaw D.R., Tahmasebi S., Bertos N.R., Yang X.J. Histone deacetylases as transducers and targets of nuclear signaling. J. Cell. Biochem. 2008, 104:1541-1552.
34. Zhu M., Li W.W., Lu C.Z. Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+. CNS Neurosci. Ther. 2014, 20:308-316.